Management of Obstructive Colon Tumors in Istanbul
1 other identifier
observational
500
1 country
2
Brief Summary
The aim of this study is to evaluate the outcome of obstructive colon cancer surgery in terms of days-to-starting adjuvant therapy and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2022
CompletedStudy Start
First participant enrolled
June 1, 2022
CompletedFirst Posted
Study publicly available on registry
June 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2024
CompletedJune 21, 2022
June 1, 2022
2 years
May 11, 2022
June 17, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Time-to-starting chemotherapy
Surgical procedures will be compared in terms of days-to-first chemotherapy
1 year
Secondary Outcomes (3)
Mortality
3 months
Morbidity
3 months
Colorectal cancer-specific quality of life (EORTC QLQ - CR29) at 1 year
1 year
Interventions
Colon resection
Any type of colostomy or ileostomy with or without bowel resection
Any palliative surgery without bowel resection
Eligibility Criteria
Adults who underwent surgery with a clinical and radiological diagnosis of obstructive colon tumors at any stage will be included in the study.
You may qualify if:
- Acute intestinal obstruction due to colon cancer either preoperatively or intraoperatively detected
- Clinical findings of obstruction (Abdominal distention and pain, nausea or vomiting, and absence of bowel movements) confirmed by abdominal x-ray or CT
You may not qualify if:
- Benign diseases
- Emergency surgery due to bleeding, perforation and other non-obstructive situations
- Recurrent colon tumors
- Rectal cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Medipol University Bahcelievler Hospital
Istanbul, 34196, Turkey (Türkiye)
Medipol Mega Hospital
Istanbul, 34214, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Osman Civil, MD
Medipol University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2022
First Posted
June 21, 2022
Study Start
June 1, 2022
Primary Completion
May 31, 2024
Study Completion
May 31, 2024
Last Updated
June 21, 2022
Record last verified: 2022-06